Table 2.

Mean serum IgG subclass trough concentrations during intravenous and subcutaneous administration of IGIV-C in patients with PIDD.^*

	Ctrough, mg/ml, mean ± s.d.
IgG subclass	Intravenous treatment phase	Subcutaneous treatment phase†	Mean change from intravenous to subcutaneous, %
IgG1	5·2 ± 1·2	6·3 ± 1·5	20·2
IgG2	3·3 ± 0·8	3·8 ± 0·9	15·2
IgG3	0·7 ± 1·2	0·7 ± 1·2	12·3
IgG4	0·4 ± 0·2	0·4 ± 0·2	11·1

^*Data are reported for the IgG population.

^†Mean C_trough for subcutaneous administration of IGIV-C was calculated from data for weeks 13, 17 and 21, if available. C_trough, trough (predose) plasma IgG concentration; IgG, immunoglobulin G; IGIV-C, immune globulin intravenous (human), 10% caprylate/chromatography purified; PIDD, primary immunodeficiency disease; s.d., standard deviation.